Glaukos, which sells micro-scale surgical devices for treating glaucoma, raised the number of shares and increased the range ahead of its upcoming IPO on Tuesday.
The Laguna Hills, CA-based company now plans to raise up to $102 million by offering 6.0 million shares at a price range of $16 to $17. The company had previously filed to offer 5.36 million shares at a range of $13 to $15. At the high end of the revised range, Glaukos will raise 36% more in proceeds than previously anticipated and its proposed diluted market cap increased by 25% to $591 million.
Glaukos, which was founded in 1998 and booked $52 million in sales for the 12 months ended March 31, 2015, plans to list on the NYSE under the symbol GKOS. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs are the joint bookrunners on the deal. It is expected to price during the week of June 22, 2015.
